Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Author Correction: Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients.
|
31804497 |
2019 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Long noncoding RNA H19 competitively binds miR-93-5p to regulate STAT3 expression in breast cancer.
|
30256448 |
2019 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the qPCR validation test, the serum levels of miR-93 were upregulated in breast cancer, breast hyperplasia, lung cancer, chronic obstructive pulmonary disease, nasopharyngeal cancer, hepatocellular cancer, gastric ulcer, endometrial cancer, esophageal cancer, laryngeal cancer, and prostate cancer compared with healthy controls.
|
30390344 |
2019 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients.
|
30154547 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Numerous reports have indicated that microRNA‑93‑5p (miR‑93‑5p) is involved in the development and progression of human cancer, including non‑small cell lung, gastric and breast cancer; however, the role of miR‑93‑5p in retinoblastoma (RB) remains unknown.
|
30365088 |
2018 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of miR-93 in breast cancer cell lines MCF-7 and MCF-7/ADM was detected by reverse transcription-quantitative PCR (RT-qPCR). miR-93 mimics and inhibitors were transfected into MCF-7/ADM and MCF-7 cells, and MTT assay was used to detect the resistance of cells to adriamycin after transfection.
|
30127988 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In short, reductive PTEN mediated by miR-106b and miR-93 promoted cell progression through PI3K/Akt pathway in breast cancer.
|
28518139 |
2017 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This indicated the triadic relationship among miR-93, EMT and drug resistance in breast cancer.
|
28765915 |
2017 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results demonstrated a novel pathway through which miR-93-5p regulates MKL-1 and STAT3 to affect EMT controlling breast cancer cell migration.
|
28499590 |
2017 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The level of miR-105 and miR-93-3p were evaluated in 25 breast cancer tumor tissues.
|
29258605 |
2017 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite advances in treatment, the highly metastatic nature of breast tumors has given rise to the urgent need for development of novel therapeutic and prognostic markers. miR-93 is known to regulate the epithelial to mesenchymal transition process and to influence metastatic spread in breast carcinoma, although the exact mechanism(s)/genes involved remain unknown.
|
27840899 |
2016 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The miR-93 expression level in TNBC tissues was significantly higher than that in non-triple-negative breast cancer tissues.
|
25238878 |
2015 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that overexpression of miR-93 in FFPE tissues may serve as an indispensable source for biomarker discovery and validation in breast cancer patients.
|
24606013 |
2014 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using a series of breast cancer cell lines representing different stages of differentiation and mouse xenograft models, we demonstrate that mir-93 modulates the fate of breast cancer stem cells (BCSCs) by regulating their proliferation and differentiation states.
|
22685420 |
2012 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We stably expressed miR-93 in the MT-1 human breast carcinoma cell line and found that tumors formed by the miR-93 cells contained more blood vessels than those formed by the control cells.
|
23111389 |
2012 |